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INTRODUCTION  
 Prostate cancer is common and remains the second leading 
cause of cancer death among elderly men. Current methods for 
its detection, like  Digital rectal examination, Transrectal 
ultrasound, Prostate Specific Antigen assay and even sextant 
biopsy have limited accuracy for most early prostate cancers. 
Moreover diagnosing carcinoma prostate in patients in grey 
zone of PSA [4 to 10 ng/ml] and patients with normal Digital 
rectal examination is still difficult. 
 There is much overlap between Benign prostatic 
hyperplasia[BPH] and carcinoma prostate in this diagnostic grey 
zone of Prostate specific antigen. The histologic diagnosis of 
prostate cancer is made, in the majority of cases, by prostate 
needle biopsy. 
    Prostate cancer rarely causes symptoms until it is advanced. 
Thus, suspicion of prostate cancer resulting in a 
recommendation for prostatic biopsy is most often raised by 
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abnormalities found on digital rectal examination [DRE] or by 
serum prostate-specific antigen (PSA) elevations. Although 
there is controversy regarding the benefits of early diagnosis, it 
has been demonstrated that an early diagnosis of prostate cancer 
is best achieved using a combination of DRE and PSA.  
 Transrectal ultrasound (TRUS)-guided, systematic needle 
biopsy is the most reliable method, at present, to ensure accurate 
sampling of prostatic tissue in men considered at high risk for 
harboring prostatic cancer on the basis of DRE and PSA 
findings.  
      This challenge in diagnosis, localization and staging of 
potentially curable early disease has prompted further research 
into radiological imaging which could be more specific and 
sensitive, and also noninvasive that provides good positive and 
negative predictive value(PPV and NPV). 
 Magnetic Resonance Imaging [MRI] is well known for its 
diagnostic potential, primarily due to its capability to 
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noninvasively generate high-resolution anatomical images based 
on various inherent tissue characteristics.1 With ongoing 
research on ways of data acquisition during MRI and their 
analysis, newer sequences and strategies have been developed 
that provide more specific information like diffusion imaging, 
functional imaging, metabolic imaging, etc., faster image 
generation and higher resolution.  
     With these newer technologies, the diagnostic potential of 
MR techniques is improving further, and its indications are also 
developing.  Magnetic Resonance spectroscopic imaging 
(MRSI) is one of these new promising techniques, and uses the 
regular MRI machine, requiring only software upgrades as an 
additional cost factor.  
     It is not only useful in diagnosing the disease but also useful 
in assessing the local extant of disease which is also important 
in cure of the disease. 
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   So this study is intented to assess the role of MR 
spectroscopy in diagnosing carcinoma prostate in patients with 
grey zone PSA with normal DRE. 
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AIM & OBJECTIVES 
The aim of this study is to 
¾ To find out the "Role of Magnetic resenonce 
spectroscopy as a noninvasive diagnostic 
investigation in carcinoma prostate” in patients 
with PSA between 4 and 10ng/ml [Diagnostic 
grey zone] and normal DRE. 
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REVIEW OF LITERATURE 
 According to the American Cancer Society [ACS], the 
incidence of carcinoma prostate is ever increasing and African 
American men are twice as vulnerable to prostate cancer 
compared to white men. Although the death rate has dropped 
over the last few years, it still remains the second leading cause 
of cancer deaths among men after lung cancer in the United 
States. 
 The ACS recommends that the PSA test and the digital 
rectal examination should be offered annually, beginning at age 
50, to men who have a life expectancy of at least 10 years and 
those men that are at higher risk like African American men and 
those men with a strong family history of one or more first-
degree relatives diagnosed with prostate cancer at an early age.  
    The survival and successful treatment of Prostatic Carcinoma 
patients is dependent upon the early diagnosis of Prostatic 
Carcinoma. 
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 Further, the ability to monitor the progression and 
regression of malignancy is critical in the management of the 
disease.  
    Currently the combination of digital rectal examination 
[DRE] and prostate-specific antigen [PSA] testing is the primary 
diagnostic procedure.  Typically, an elevated PSA or a nodule 
detected on physical examination prompts an evaluation and an 
eventual transrectal ultrasound-guided (TRUS) biopsy may 
reveal cancer.  
     However in most cases, positive identification of Prostatic 
Carcinoma only becomes evident when malignancy has been 
established and the cancer has metastasized beyond the capsular 
region of the prostate.  
 Hence detection of prostatic carcinoma within grey zone of 
PSA [4-10 ng/ml] with normal DRE is critical. Here, MRI in 
conjunction with endorectal / pelvic surface coil provides 
superior visualization of zonal prostate anatomy compared to 
 8
TRUS2.  MRI by itself can however be limited, as various 
pathologies can mimic cancer thus compromising the diagnosis. 
    In recent years, magnetic resonance spectroscopy of the 
prostate has shown to provide very useful metabolic information 
of the prostate.  The combined used of MRI and MRSI has 
shown to increase the sensitivity and specificity in the detection 
of prostate cancer3. 
Citrate Metabolism 
 The metabolism of normal mammalian cells involves the 
complete oxidation of glucose and fat through the intermediary 
steps involving the synthesis and oxidation of citrate via the 
Krebs cycle4. Coupled with phosphorylation, this intermediary 
synthesis and oxidation of citrate is essential for the cells to 
generate their major supply of cellular energy through the 
production of ATP.  
 The citrate synthesized during this process in the Krebs 
cycle forms the source for acetyl-CoA required for lipogenesis. 
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The Krebs cycle and the recycling of its intermediates are 
essential for the various reactions of amino acid metabolism.   
These established pathways are essential to normal mammalian 
aerobic cell metabolism, cellular function, survival, growth, and 
reproduction5.  
    The normal human prostate on the other hand does not go 
through the process of citrate oxidation thus accumulating large 
amounts of citrate which essentially is the end product of the 
intermediary metabolism.  Cooper and Imfeld were the first to 
report that citrate levels were significantly decreased in prostate 
cancer tissue compared to the normal prostate or BPH6.  Shortly 
thereafter the same group suggested that the biochemical 
alterations seen through altered citrate metabolism may well 
occur before any malignant changes are histologically obvious7.  
While these observations were made over four decades ago, it is 
only in the last decade that scientists have been paying attention 
to the measurement of citrate levels within the prostate. 
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    The altered citrate metabolism has now been further studied 
by Costello, Franklin and their colleagues who have shed some 
light on the role of zinc in the production of citrate8, 9. 
 In addition to citrate, the normal and BPH prostate also 
accumulates high levels of zinc. The level of zinc in the normal 
prostate is about 150μg/g of tissue wet weight.  However, the 
levels of zinc and citrate are not uniformly distributed 
throughout the prostate gland. For example in the normal 
peripheral zone there is high level of zinc concomitant with high 
levels of citrate.    
 In the normal central gland, the levels of zinc and citrate 
are at a lower concentration10.  It is thought that in the presence 
of zinc, the mitochondrial aconitase activity that is responsible 
for citrate oxidation is severely limited in the normal prostate 
epithelial cells, which ultimately leads to the accumulation of 
citrate. The accumulation of citrate comes at the cost of ATP 
production which is reduced by about 65% in the normal 
prostate epithelial cells (14 moles of ATP) compared to other 
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normal mammalian cells (38 moles of ATP) that completely 
oxidize glucose. 
 In prostate cancer however, the ability of 
intramitochondrial accumulation of zinc diminishes. It is 
thought that such a decrease in the zinc level restores the  
m-aconitase activity that leads to increased citrate oxidation. 
This is coupled with ATP production essential for progression 
towards malignancy9, 11, 12.   
     While many aspects of the zinc-citrate relationship are still 
under investigation, there is ample evidence suggesting that 
zinc-citrate interactions play an important role in the 
pathogenesis and progression of prostate malignancy. 
Magnetic Resonance Imaging 
 Recent studies show that the combined use of an 
endorectal and phased-array coil and a high field strength MR 
imaging system provides the highest image resolution possible 
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(2).  MR imaging accurately depicts internal prostatic zonal 
anatomy and displays the physiologic complexity of the gland.  
 Over the past several years, the superiority of MRI in the 
staging accuracy of cancer involving the peripheral zone has 
been consistently reported between 75% and 90%3.   
 
 
MRI showing malignant focus in peripheral zone 
      Most prostate cancer involves the peripheral zone of the 
gland, where cancer is identified as low signal abnormality on 
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T2-weighted imaging.  Although MRI has allowed intra-
prostatic evaluation of tumor location, results are often non-
specific13. Torricelli et al showed that cancer could mimic post-
biopsy hemorrhage, scar, prostatitis, or interglandular dysplasia 
on MR imaging of the prostate with specificity in the order of 
50% 14. 
Magnetic Resonance Spectroscopy 
 MRSI is a powerful tool that can provide useful biological 
information associated with many different metabolites15.  
Proton (1H) spectroscopy is attractive in terms of sensitivity, 
spatial resolution, signal to noise, and acquisition time.   It has 
been widely used in the brain and its application and availability 
for imaging various anatomical regions of body has been 
increasing. 
 MRS can provide a description of the chemical makeup of 
an imaged area in order to determine the presence of  
cancer16. Molecules that can be studied with MRS include water, 
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lipids, choline, citrate, lactate, creatine, and amino acids15. 
Based on the initial work by Costello and Franklin at the 
University of Maryland, the prostate gland is unique in the body 
by the fact that it contains high levels of citrate17.  
    As the normal glandular epithelial cells are replaced by 
cancer, the concentration of citrate and choline change in the 
transformation to a malignant state. Choline levels increase and 
citrate levels decrease in the presence of active cancer4.  
     As mentioned above, the reason for the decline in the levels 
of citrate is the altered intermediate metabolism in the Krebs 
cycle5. Although the mechanism for the elevation of the choline 
peaks is less understood, just as in the case of brain 
spectroscopy, its elevation is thought to be associated with 
changes in cell membrane synthesis and degradation that is 
normally associated with cancer. 
 The choline resonance observed in-vivo at 3.22 ppm, 
sometimes referred to as total choline arises from the methyl 
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hydrogens of trimethylamines and is comprised of choline, 
phosphocholine (PC),glycerophosphocholine (GPC), 
phosphoethanolamine (PE), glycero-phosphoethanolamine 
(GPE), and ethanolamine18-22.  These compounds are essential in 
the synthesis and hydrolysis of phosphatidylcholine and 
phosphatidylethanolamines that are an integral part of the 
characteristic bilayer structure of cells and regulate membrane 
integrity and function. 
 Polyamines such as spermine can be visualized in prostate 
MRSI23. Polyamines are involved in many cellular processes 
such as maintenance of DNA structure, RNA processing, 
translation and protein activation24,25.   Disruption to the 
synthesis of polyamines is known to modulate the genetic 
effects of these genes.  Polyamines can be visualized in proton 
MRSI as a broad peak between choline and creatine.  
    Normal prostate epithelial cells will demonstrate large 
amounts of citrate and polyamines. The malignant cells on the 
other hand exhibit low levels of citrate and polyamines to the 
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extent that the choline and creatine resonances are resolved to 
the baseline.  
 One unfortunate consequence of prostate MRSI is the 
inability to monitor metabolites such as lactate and lipids in vivo 
due to the necessity for suppressing lipids to minimize 
contamination from the lipids surrounding the prostate gland. It 
has been shown in vitro that the citrate to lactate ratio can be 
used to discriminate prostate cancer from BPH and that the ratio 
can be used as an indicator of cancer aggressiveness7. It is hoped 
that future MRSI improvements will allow for the interrogation 
of these metabolites. 
MRSI Techniques 
 Although significant developments have been made with 
MRSI of the brain, the translation of this technology to other 
body parts including the prostate gland has proven to be far from 
trivial. 
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 In the case of the prostate gland, the deep location of the 
prostate, the possible movement of the prostate gland during the 
MRSI acquisition, and the dominating triglyceride signals from 
the surrounding adipose tissues often pose a challenge in 
obtaining reliable quality spectra. Initial studies employing 
prostate spectroscopy used single voxel techniques such as 
STEAM (Stimulated Echo Acquisition Method) and PRESS 
(Point Resolved Spectroscopy) using the body coil26-29. 
 
 
MRSI showing voxels 
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 Usually the voxel size was large and encompassed both the 
peripheral zone and the central gland. Although these techniques 
showed the feasibility for performing proton spectroscopy, their 
use in the clinical setting was limited due to long scan times and 
the poor signal to noise of the spectra. [fig-1]. 
 However, with the arrival of 2D and 3D MRSI techniques 
the interest in prostate spectroscopy has increased30-33.  Several 
technical hurdles had to be overcome to reliably detect the 
resonances from the biological relevant compounds in the 
prostate including accurate localization and the suppression of 
large signals from both water and lipids34-37. 
 3D-MRSI technique appears to be the most suitable for the 
prostate gland as it is able to provide the prostate metabolite 
level information with high spatial resolution for the entire 
gland. Typically PRESS localization and band selective 
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excitation with gradient dephasing (BASING) for water and 
lipid suppression is used34.   
    3D-MRSI provides an array of spectra from contiguous 
voxels from the entire prostate gland. The contiguous array of 
spectra that map the entire prostate are in alignment with the 
anatomical T1- and T2-weighted images allowing for a 
comparative interpretation between the anatomical images and 
the metabolic information.   
     Investigators at the University of California San Francisco 
(UCSF) showed that 3D-MRSI can be used to differentiate and 
localize the tumor foci to a volume as small as 0.24cc38-42. 
Similar results have been reported by the group in the University 
of Nijmegen, Netherlands who further refined the 3DMRSI 
technique by using elliptical encoding to further reduce the scan 
time43-45. 
 Interpretation resulting from a combined evaluation of the 
MR images and by metabolic changes observed through MRSI 
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leads to the most confident identification of cancer with a 
specificity of up to 98% (43). Decreased signal intensity on T2-
weighted images in conjunction with decreasing levels of citrate 
and polyamines and a concomitant increase in the levels of 
choline increases the specificity in the diagnosis of prostate 
cancer. Hence an increased choline to citrate ratio is usually 
used as a method for depicting prostate cancer. Since the choline 
and creatine resonances are inseparable for quantification 
purposes, most investigators use [Choline+Creatine]/Citrate 
(CC/C) for spectral analysis. 
 A standardized scoring method was developed by Jung et 
al which is based on the deviation of the CC/C ratio from its 
normal value of 0.22±0.013. A voxel CC/C value within one 
standard deviation of this normal value was given a score of 1, a 
value between 1 and 2 standard deviations was given a score of 
2, a value between 2 and 3 standard deviations was given a score 
of 3, a value between 3 and 4 standard deviations was given a 
score of 4, and a value greater than 4 standard deviations was 
assigned a score of 5. 
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 Additional adjustments were made to the score to account 
for the elevation of choline over creatine, reduced polyamines, 
and poor signal to noise rations. In these  way each voxel 
obtained a score between 1 and 5 which was designated to an 
interpretative scale of likely benign, probably benign, equivocal, 
probably malignant and likely malignant corresponding to a 
voxel score from 1-5 respectively. Using this standardized five-
point scale they were able to show good accuracy and excellent 
interobserver agreement.  
     It should be noted that 3D-MRSI produces vast amounts of 
spectroscopic data and a standardized scale such as the one 
developed by Jung et al is likely to make the task of spectral 
interpretation less formidable46.  Such standardized scales will 
allow one to easily characterize the tumors aggressiveness and 
spatial extent. 
  The combination of MRI and MRSI in conjunction 
with the endorectal and phased-array body coil is emerging as 
the most sensitive tool for anatomic and metabolic evaluation of 
the prostate gland3,47,48. 
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      Improvements in pulse sequences and MR technology have 
enabled the acquisition of the metabolic information from the 
entire prostate at high resolution within a reasonable time of ten 
minutes or less. 
       Proton MRI/MRSI may be of great value for patients who 
are at increased risk for prostate cancer, for patients who have 
chosen watchful waiting, for longitudinal follow up from 
therapy, and in guiding various localized therapeutic  
treatments 49-51. 
 MRI/MRSI of the prostate gland is likely to benefit from 
the recent trend towards ultra-high field magnet systems and 
emergence of multi-channel parallel imaging52-54.    
     Further newer techniques such as diffusion and perfusion are 
likely to increase the sensitivity and specificity of prostate 
cancer detection and characterization55-63. 
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PROSTATE IMAGING 
 TRUS of the prostate, first described by Wantanabe and 
colleagues64, expanded to routine clinical use with 
improvements in ultrasound technology and the introduction of 
the TRUS-guided systematic sextant biopsy protocol by Hodge 
and associates65,66.  
     Concurrent with improved biopsy techniques, the use of PSA 
screening increased the number of men undergoing early 
prostate cancer screening and prostate biopsy, with estimates as 
high as 800,000 biopsies annually in the United States  
alone67.  
   Given the prevalence of prostate cancer and the frequency 
with which TRUS-guided prostate biopsies are performed, 
significant efforts have been focused on determining the 
appropriate indications for biopsy and the ideal technique by 
which to image and biopsy the prostate. 
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 TRUS technology has become a mainstay of many image-
guided prostate interventions, including prostate biopsy, 
brachytherapy, cryotherapy, and high-intensity focused 
ultrasound (HIFU), as well as being used in the evaluation of 
appropriate patients for treatment of benign prostatic hyperplasia 
(BPH)68. 
 ULTRASONOGRAPHIC ANATOMY OF THE 
PROSTATE  
 The prostate lies between the bladder neck and the 
urogenital diaphragm, just anterior to the rectum, an ideal 
position to be imaged via TRUS. The prostate gland is 
traditionally described based on a pathologic zonal architecture. 
These divisions consist of the anterior fibromuscular stroma 
(AFS) that is devoid of glandular tissue, transition zone (TZ), 
central zone (CZ), periurethral zone, and peripheral zone (PZ). 
Unfortunately, these regions are not visible sonographically as 
distinct entities.fig-2. 
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 However, the TZ may often be discernible from the PZ 
and CZ, particularly in glands with significant BPH. Located 
posteriorly, the normal CZ and PZ, from which a majority of 
adenocarcinomas arise, have a homogeneous echogenic 
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appearance whereas the anteriorly situated TZ is more 
heterogeneous. 
 
Fig-2. Normal appearance of prostate in TRUS 
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Prostate Cancer Imaging on TRUS  
 All hypoechoic lesions within the PZ should by noted and 
included in the biopsy material. The lack of a distinct 
hypoechoic focus does not preclude proceeding with biopsy 
because 39% of all cancers are isoechoic and up to 1% of 
tumors may be hyperechoic on conventional gray-scale  
TRUS69.  Despite the higher prevalence of cancers discovered in 
prostates with hypoechoic areas, the hypoechoic lesion itself 
was not associated with increased cancer prevalence compared 
with biopsy cores from isoechoic areas in a contemporary series 
of almost 4000 patients70. fig-3 
 
Fig-3. TRUS image of prostatic carcinoma. 
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Color and Power Doppler TRUS  
 Color Doppler imaging is based on the frequency shift in 
the reflected sound waves from the frequency of insonation and 
thus depicts the velocity of blood flow in a directionally 
dependent manner .   
       Color assignment is based on the direction of blood flow 
related to the orientation of the transducer receiving the signal; 
flow toward the transducer is depicted in shades of red and flow 
away in shades of blue; the color is not specific for arterial or 
venous flow.  
       Power Doppler utilizes amplitude shift to detect flow in a 
velocity and directionally independent manner71. The 
advantages of power Doppler imaging are its ability to detect 
slower flow and to have less reliance on the Doppler angle, 
making it more suitable for detection of prostate cancer 
neovascularity.  
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      Although power Doppler imaging offers improved 
sensitivity to small amounts of flow, neither modality has yet 
proved itself superior to the other for cancer detection. 
Enhancements in the technical aspects of color Doppler TRUS, 
including the use of contrast agents , may provide the necessary 
improvements to specifically identify cancer sites in the 
future.fig-4. 
 
Fig-4. TRUS with color and power Doppler. 
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     A new sonographic technique known as elastography may 
prove to be superior to color Doppler imaging in  
identification of malignant areas in the prostate72,73. This 
technique employs real-time sonographic imaging of the 
prostate at baseline and under varying degrees of compression.  
Through computerized calculations, differences in displacement 
between ultrasonic images from baseline and during 
compression may be visualized and regions with decreased 
tissue elasticity may be tagged as suggestive of malignancy.  
fig-5.  
 
Fig-5.  Elastography of prostatic carcinoma 
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 New Doppler, contrast medium–enhanced, and other 
developing techniques have the potential to allow accurate 
localization and diagnosis of prostate cancer and minimize or 
eliminate the need for multiple biopsy sites to diagnose prostate 
cancer in the future. However, until these techniques are proved 
superior in the localization of prostate cancer, systemic TRUS 
gray-scale core needle biopsy will continue to be regarded as the 
“gold standard” for the diagnosis of prostate cancer. 
 A variety of imaging modalities have been evaluated for 
staging prostate cancer. None of these techniques are sensitive 
enough to detect reliably the extraprostatic spread of prostate 
cancer. The inability to image microscopic disease limits the 
accuracy of current imaging modalities. 
 Radionuclide bone scan (bone scintigraphy) is the most 
sensitive modality for the detection of skeletal metastases. This 
is in contrast to bone survey films (skeletal radiography), which 
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require more than 50% of the bone density to be replaced with 
tumor before they can identify distant spread. 
 Today, skeletal radiography is obtained only to confirm a 
positive bone scan in men at low risk for bone metastases. 
Radionuclide bone scan can also screen for upper urinary tract 
obstruction and thus can obviate the need for further evaluation 
of the urinary tract in men with prostate cancer. 
 
 Because bone metastases at diagnosis are rare in men 
without bone pain in the PSA screening era, the routine use of 
bone scans in this population may not be useful and can create 
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needless stress by detecting benign conditions that require 
further tests to rule out occult malignant disease.  
 In addition, a strategy of using bone scintigraphy in the 
staging evaluation of all PSA-screened men may not be cost-
effective. Bone scans are not routinely obtained for patients with 
PSA levels less than 10 ng/mL and no bone pain. When a bone 
scan is performed, however, it provides a baseline evaluation for 
comparison in men who later may complain of bone pain. 
 The use of computed tomography (CT) and MRI to 
evaluate the local extent of disease and the possibility of nodal 
involvement is not routinely recommended because of the low 
sensitivity of these modalities. 
 Such tests may be appropriately reserved for high-risk 
patients such as those with locally advanced disease by DRE, a 
PSA greater than 20 ng/mL, or men with poorly differentiated 
cancer on needle biopsy. 
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 Furthermore, the cost effectiveness of these tests in 
populations with probabilities of lymph node involvement less 
than 30% has been questioned. Given the rarity of lymph node 
involvement in screened populations, it appears that these 
imaging modalities are being overused in the staging of prostate 
cancer. 
 Combined MRI and MRI spectroscopy (MRIS) are being 
evaluated for staging prostate cancer, but there is no evidence 
that these methods will overcome the current limitation of the 
inability to image microscopic disease.  
 Specialized techniques such as high-resolution MRI used 
in tandem with the intravenous administration of lymphotropic 
superparamagnetic nanoparticles may allow the detection of 
small and otherwise undetectable lymph node metastases in 
patients with prostate cancer. These techniques, however, 
require further clinical evaluation before widespread use. 
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MATERIALS AND METHODS 
Title of study   
 "Role of Magnetic resenonce spectroscopy as a 
noninvasive diagnostic investigation in carcinoma 
prostate”  in patients with PSA between 4 and 10ng/ml.  
[Diagnostic grey zone] and normal DRE. 
¾ Period of Study 
September 2008 - April 2011 
Type of Study 
Prospective Study 
Ethical committee approval obtained 
Source of patients 
 Patients  with obstructive lower urinary tract 
symptoms who presented  to  the  Department of Urology, 
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Madras Medical College, Government General Hospital, 
Chennai. 
PATIENT SELECTION 
Inclusion Criteria 
` 20 males with age between 50 - 78 yrs 
` PSA between 4 and 10 ng/ml 
` Normal DRE 
` Proper consent obtained 
` No other co morbidities 
Exclusion criteria 
Patients with 
` UTI 
` Bleeding disorder 
` Claustrophobia 
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` Nodular DRE 
` Patients with AUR 
` Patients with prostatitis  
` Patients with implants  
Patient preparation 
 Pre procedural antibiotics tab.ciprofloxacin-500mg 
half an hour prior to procedure and rectal enema were 
given. 
 Viral serology done. All the patients are explained 
about the procedure. 
Patient position  
 Supine position for MRSI and left lateral position 
for TRUS and Biopsy. 
 38
IMAGING EXAMINATION 
MR Spectroscopy 
 All the twenty patients were subjected to undergo 
MRS. The machine used in this study is siemens 1.5 tesla 
surface coil machine. MRI study of prostate with 3DCSI 
MR Spectroscopy done.fig-6. 
 High resolution Axial, Sagittal and coronal T2WI, T1 
Axial and 3D CSI MRS technique was used. 
 The signal intensities of prostate gland involving 
lateral lobes, median lobe and periurethral glandular region 
were analyzed. 
 The prostatic volume is measured. The appearance of 
prostatic capsule, bladder wall appearance any thickening, 
irregularity were noted. The seminal vesicle appearance 
noted. 
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 3D MV MRS of prostate was analyzed. The choline 
integral values and citrate integral values were analyzed. 
Any significant increase or decrease in each voxel were 
noted. The choline/citrate ratio is calculated. 
 Any increase in choline/citrate ratio more than 2SD is 
considered as abnormal and indicative of malignancy in 
each voxel. In our study this ratio more than or equal to 1.2 
is considered as malignancy.fig-7. 
 Retro peritoneal lympyadinopathy if present was 
noted. 
TRUS scan and TRUS guided biopsy 
 All the twenty patients were subjected for TRUS scan 
with 7 Mhz Aloka machine with rectal probe in left lateral 
position. Complete zonal anatomy of prostate was studied. 
Systematic sextant biopsies of 13 core were taken. Each 
biopsy specimen is specifically labeled according to the 
 40
orientation of biopsy site and sent for histopathological 
examination. 
 All the patients were given one dose of ciprofloxacin 
500 mg half an hour prior to TRUS biopsy. All were given 
low rectal enema prior to biopsy. 
 No patient developed any untoward complication 
following the procedure. 
Statistical Analysis:  
      Statistical analysis was done with SPSS software. 
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OBSERVATION AND RESULT 
Total No of patients studied: 20. 
The patients ranged in age from 50 to 75 years, with a 
mean age of 31.21 years. 
The prostate volume ranged from 40 to 60 ml. 
The gleason sum was between 4 and 7. 
 Positive for 
malignancy 
Negative  for 
malignancy 
MRS 8/20 12/20 
TRUS Bx 6/20 14/20 
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DISCUSSION 
 The triad of DRE, serum PSA, and TRUS-directed 
prostatic biopsy is used in the early detection of prostate cancer. 
The combination of DRE and serum PSA is the most useful 
first-line test for assessing the risk of prostate cancer being 
present in an individual74-78. 
 TRUS is not recommended as a first-line screening test 
because of its low predictive value for early prostate  
cancer78-81 and high cost of examination. 
 The effectiveness of PSA as a screening method for 
prostate cancer is debated. However, it has been proved that use 
of PSA increases detection rates of prostate cancer and leads to 
the detection of prostate cancers that are more likely to be 
confined when compared with detection without the use of PSA.  
 This has been documented in population-based data, 
observational studies, and randomized screening trials. 
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 An increase in detection lead time for a disease with a 
long natural history can increase the probability of 
detecting cancers with more favorable biology and those 
that are unlikely to pose a threat during the host's remaining 
life82. 
 The choice of a PSA threshold or cut point above which 
one would recommend further evaluation to rule out prostate 
cancer (prostate biopsy) is controversial83-85.   
     The PSA threshold that most efficiently leads to the detection 
of life-threatening cancers while avoiding unnecessary testings 
like PSA measurements and biopsies and overdiagnosis is not 
known.  
     The controversy stems from the following the use of higher 
PSA thresholds risks missing an important cancer until it is too 
late for a cure, whereas the use of lower PSA thresholds 
increases not only unnecessary biopsies but also the proportion 
of biopsies that identify clinically insignificant disease like 
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disease that would not have been detected in the absence of 
screening. The use of a PSA threshold of 4.0 ng/mL for men 
older than 50 years has been accepted by most clinicians as 
striking a reasonable balance between these tradeoffs. 
 Morgan and colleagues86 have shown that the PSA cutoff 
value that results in 95% sensitivity with the detection of 95% of 
cancers is close to 4.0 ng/mL for men between the ages of 50 
and 70 years the target population for screening at present and 
2.5 ng/mL  for men age 40 to 50 years. 
 Improvements in test sensitivity are associated with 
the tradeoff of reduced specificity [correct exclusion of 
cancer in men who do not have the disease] and lead to an 
increase in the numbers of unnecessary biopsies. 
 PSA elevations below 10 ng/mL in men with a DRE that is 
not suspicious for prostate cancer are more likely the result of 
Benign prostatic enlargement (BPH) and represent “false” 
elevations. Distinguishing between men who have PSA 
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elevations driven by BPH or cancer is difficult because PSA is 
not specific for cancer and the prevalence of BPH in the 
population is high compared with prostate cancer. 
 Volume-based PSA parameters [with prostate volume 
determined by ultrasonography] including PSA density [PSA 
divided by prostate volume], complexed PSA density 
[complexed PSA divided by prostate volume], and PSA 
transition zone [PSA divided by transition zone volume] have 
been evaluated as methods for excluding men with PSA 
elevations related to BPH. 
 Specificity of PSA velocity using a cut point of 0.75 
ng/mL per year remained high (over 90%) when PSA levels 
were between 4 and 10 ng/mL or below 4 ng/mL, but 
sensitivity for cancer detection was 11% at levels below  
4 ng/mL, compared with 79% for levels between 4 and  
10 ng/mL. 
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 The cutoff for percentage of free PSA that optimizes 
sensitivity and specificity for cancer detection depends on 
prostate size because overlap in the percentage of free PSA is 
greatest among men without cancer who have enlarged prostates 
and men with cancer in the setting of prostate enlargement87. 
 Maintaining a sensitivity for cancer detection of 90% 
among men with PSA levels between 4 and 10 ng/mL and 
nonsuspicious DREs, Catalona and associates87 found that a free 
PSA cutoff of 23% [biopsy only if 23% or less] would have 
eliminated 31% of unnecessary biopsies in men with prostate 
glands larger than 40 cm3, whereas a free PSA cutoff of 14% 
would have eliminated 76% of unnecessary biopsies in men 
with prostate glands smaller than 40 cm3. 
 Enthusiasm for using TRUS to identify early prostate 
cancers by detection of hypoechoic lesions has not been justified 
with longer follow-up .  
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      A number of studies have confirmed the inability of TRUS 
to localize early prostate cancer80,81,88, So to avoid unnecessary 
TRUS biopsies at the same time detecting carcinoma in patients 
with grey zone PSA is a challenging task. 
 TRUS biopsies are limited by a low sensitivity of 60%, a 
PPV of only 25% and false-negative rate estimated to be as high 
as 15–34%89,90. Combining MRSI with TRUS-guided biopsy 
could help in (i) directing biopsy to the suspicious area and 
therefore improve its detection rate, and (ii) avoiding the biopsy 
in those who have no suspicious lesions and therefore avoiding 
all risks associated with an invasive biopsy. 
 3D MRSI data can be overlaid on corresponding  
T2-weighted MRI images to identify the anatomical and 
pathological location of spectroscopic voxels. Tri-planar 
coordinates of the suspicious area can thus be obtained and used 
to take a biopsy from the suspicious area under TRUS  
guidance91.  
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      The addition of MRSI to MRI has been shown to improve 
the localization of cancer to a sextant of the prostate, with a 
sensitivity of up to 95% and a specificity of 91% when 
compared with MRI alone (P< 0.05)92,93.  
       Prospectively evaluated the role of MRI/MRSI in men with 
a PSA level of < 10 ng/mL, who have poorest cancer detection 
rate and the highest false-negative rate on TRUS biopsy, and 
found a cancer detection rate about three times better, and a 
NPV approaching 100%91,94. 
 In our study we have investigated 20 patients, out of which 
8 patients were MRS positive for malignancy and all the 20 
patients were subjected to under go TRUS biopsy 0f targeted 
and extended core biopsy which 6 out of 8 who were positive 
for malignancy by MRS were positive for malignancy. 
 The results were analysed by SSPS software and the 
following statistical reports were arrived. 
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 In our study the sensitivity of MRS is 100% with a 
confident interval of 95%. 
 The specificity of  MRS  is  87% with  confident  interval  
of  95% [56.2-97.5]. 
       The positive predictive value is 75% with confident interval 
of 95% [35.6-95.5]. 
 The negative predictive value is 100% with confident 
interval of 95% [69.9-100.0]. 
 The correlation of co-efficients showed that, Age vs MRS 
score is 0.420 and the P value is 0.065, statistically insignificant. 
 Prostate volume vs MRS score is 0.459 and the P value is 
0.042 and statistically significant. [P<0.05] 
 PSA vs MRS score is 0.461 and the P value is 0.041 and 
statistically significant. [P<0.05] 
 Gleason sum vs MRS score out of 6 MRS and TRUS Bx 
proven malignant patients is 0.057 and P value is 0.237. 
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 In  other  studies done by Sheidler et al,  Kumar et al, 
Coakley et al  [92-94] showed sensitivity of 95%, and 
specificity of 91% with negative predictive value approaching to 
100%. 
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CONCLUSION 
 MR spectroscopy of prostate for patients with grey 
zone PSA and normal DRE is a non invasive and feasible 
option to detect carcinoma prostate with a Positive 
predictive value of 75% and Negative predictive value of 
100%. 
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 “MAGNETIC RESONANCE SPECTROSCOPY AS A NONINVASIVE DIAGNOSTIC 
INVESTIGATION IN CARCINOMA PROSTATE”  
 PROFORMA 
NAME:                                                               AGE & SEX 
ADDRESS: 
PHONE NO:                                                           URO  NO:            
HISTORY: 
 LUTS; 
DM/HT/PT                                                      H/O DRUG INTAKE 
PREVIOUS INTERVENTION/ SURGERY 
G/E: 
GENITALIA: 
P.R: 
INVESTIGATIONS: 
 Basic blood investigations ,Urine routine and C/S, RFT 
Coagulation profile 
USG-KUB 
PSA 
MRI MR spectroscopy 
TRUS scan & Biopsy 
                      
 MASTER CHART 
s.no  Name  age  symptom RFT  PSA  Pr.volume       DRE  Cho/cit 
TRUS‐
Bx 
 gleason 
sum 
1  subramani  64  Obst  N  8.6 28cc  gr‐1  1.6
Adeno 
ca  2+2 
2  Palani  62 Asympt  N  4.3 35cc  gr‐2  0.4  BPH    
3  Ganesan  74 Obst  N  8 32cc  gr‐2  1.5
Adeno 
ca  3+2 
4  Krishnamoorhy  70 Obst  N  8.2 32cc  gr‐2  1.5
Adeno 
ca  3+2 
5  Narayanan  50 Obst  N  8.04 30cc  gr‐2  0.8 BPH    
6  Doss  65 Obst  N  4.8 37cc  gr‐2  0.6 BPH    
7  Dasan  70 Obst  N  6.2 30cc  gr‐2  1.6
Adeno 
ca  3+3 
8  Raman  72 Obst  N  8.06 32cc  gr‐2  1.8
Adeno 
ca  3+4 
9  Avinasi  70 Obst  N  9.6 36cc  gr‐2  0.6 BPH    
10  Moorthy  56 Obst  N  4.8 30cc  gr‐1  0.8 BPH    
11  Rajaram   62 Obst  N  4.6 32cc  gr‐2  0.4 BPH    
12  Ramsing  68 Obst  N  4.6 30cc  gr‐1  0.5 BPH    
13  Joseph  65 Obst  N  6.2 30cc  gr‐1  1.5
Adeno 
ca  3+3 
14  Subramani  70 Obst  N  9.2 32cc  gr‐2  0.6 BPH    
15  Rangan  68 Obst  N  4.2 30cc  gr‐1  1.2 BPH    
16  Muthu  62 Obst  N  6.2 38cc  gr‐2  0.6 BPH    
17  Singaram  60 Obst  N  4.8 30cc  gr‐2  0.5 BPH    
18  Philip  64 Obst  N  8.2 30cc  gr‐1  1.2 BPH    
19  Kesavan  68 Obst  N  4.8 32cc  gr‐2  0.5 BPH    
20  Murugan  60 Obst  N  4.2 36cc  gr‐2  0.6 BPH    
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